U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. - Wikidata - wikimedia - TriplyDB

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q33408443

about

DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets Novel strategies to target the ubiquitin proteasome system in multiple myeloma Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5 Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo Oral therapy for multiple myeloma: ixazomib arriving soon.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.Proteasome Inhibition After Burn Injury Carfilzomib reverses pulmonary arterial hypertension.Thrombotic microangiopathy during carfilzomib use: case series in Singapore.Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.Targeted therapies for cutaneous T-cell lymphomas.Panobinostat: a review of trial results and future prospects in multiple myeloma.Role of decorin in multiple myeloma (MM) bone marrow microenvironment.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Effects of β-catenin on differentially expressed genes in multiple myeloma.Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.Manipulation of viral infection by deubiquitinating enzymes: new players in host-virus interactions.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.

P2860

Q26741797-F23CCB23-A9B8-4C31-91AC-6D7A22A0FDA3 Q26773246-AFC8A64F-7E38-4302-B4AC-BCD2298E4B1C Q27026951-017E1C44-F783-4596-A8D5-0E57C6B13978 Q28392681-D886323E-0431-47F7-B491-0AF4ED7D8129 Q33414827-18EE7668-A7C4-4A8D-B573-79146735B824 Q33429346-FE9545E3-2A19-4819-82B2-68315B70CB2B Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC Q33701777-1B1BA21E-7D7D-481B-9A78-A51B74D0C8AA Q33862782-D751D194-8640-48D7-8847-1E6A91010AED Q33977088-8B0448C2-6333-40AD-A73A-BB63A0581008 Q34047916-3346BBD9-4FC8-4076-A42D-A50CA49567C6 Q34218976-C167968C-061D-4CB8-BC1C-47D1525FA962 Q34398390-0D725A98-BB1A-4C0B-8998-B47A4E34EFD1 Q34788381-90BA52A7-F206-45C2-9FF0-CBAA0F82840E Q35007061-3D4A9CC8-B0A7-47D0-AAE2-340754461B2B Q35168766-88CD414E-9D8C-4F4E-BF03-CBB89C000223 Q35444159-B52465B5-078A-44C0-B093-3BD7C816BE83 Q35555565-8246068E-581F-48C5-985D-CDA0C54EB767 Q35663049-93613961-1831-463B-BED8-899D2FBEB138 Q35764713-B061F83E-8809-405B-9B11-7E875C3AAD50 Q35895152-B80A3712-A424-4EDF-B038-AFA962D7A896 Q35933211-01208C73-2024-41E2-8B95-46A2B1ED83C3 Q35969785-147D0C0F-BDE5-45CC-9123-DC77B301DA93 Q36274834-D37D8A11-3C8D-4F79-BDB1-C3F76FF2E347 Q36487994-99966F4A-1A6B-42C1-9179-519A1B5ED9A2 Q36812649-6E5C8D9E-4C12-4A2E-BDBD-5C9DC71FEFA2 Q37271015-DF98D900-240F-4CE5-9A88-01B21EFD1526 Q37301751-C4F4DA01-1B98-4986-AA77-A5C8B38CC925 Q37427124-9C674FD6-7062-4B05-94D9-2209FFF7FD35 Q37684348-FEC6F5B3-B688-448D-8A0A-3B8B453C9EED Q38161514-2653872B-3AFC-418E-9CD6-45A5A4762F80 Q38229634-897B8F7F-8625-44B8-B59D-205BE14151A1 Q38269612-EAED233F-7E73-4ABB-8317-453C7846A108 Q38302987-6B04F414-A16C-43E2-A0E4-F14ABD05CC3C Q38400460-5802C7BE-9920-417A-BD45-D4FD9C0ECE32 Q38459874-C0149997-668E-413D-B00F-CAD45C8C5A2F Q38644746-C02C7B97-A95B-4904-A906-C1D8521E8506 Q38803414-8D9672DE-5C43-4E07-AF53-6759B7FA456E Q38807562-1C3C0828-1B30-4F93-961B-D6F6FBADD0F8 Q38860336-A04FA398-4435-4C99-B6FA-88172130C636

P2860

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q33408443

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@ast

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@en

type

label

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@ast

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@en

prefLabel

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@ast

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@en

P1433

Q33408443-FDD9DB03-EF99-4332-8585-AD16EBFE3CBC

P1476

Q33408443-AB8E33F0-F69B-432B-8D80-B71BCC03E208

P2093

Q33408443-049114C5-5A56-43F3-ABC7-9FBCB7269874

Q33408443-0CE8464C-C554-4FBA-8E77-1B705049BF77

Q33408443-167DD8E9-A939-45EE-B51C-503E64389529

Q33408443-1AAA156E-F2FA-43CC-9F75-075037B360C2

Q33408443-2947AD73-3ABF-482A-88D5-E4C2A464C974

Q33408443-2F6FC272-6C83-4B7A-A5C7-509C4C760355

Q33408443-35136F49-65F1-45BA-92D0-6A90E42AB720

Q33408443-45978600-CA9E-4F96-9349-6312CEEEF563

Q33408443-5B155EE8-1831-49B1-8623-007B41881998

Q33408443-5FF946B2-B4F1-462E-A4C1-3846E167DA4E

P304

Q33408443-EEDDFB70-78E7-4D1F-99A8-E6FFAAB0BEB4

P31

Q33408443-D35DFB2F-D0C9-4D83-90CF-B82BDE1EA74C

P356

Q33408443-2EF48F86-FF9E-45D6-BBFC-145EF5879E1F

P407

Q33408443-41D0E832-668A-4008-AA17-C7AA8FB645A4

P433

Q33408443-7F3F557C-E0E9-44CC-96F1-10C41D242488

P478

Q33408443-171B7595-7489-42C3-81B7-CA42E035AF81

P577

Q33408443-094BC4DE-3F4B-4D9B-83EE-2664E761AFE4

P698

Q33408443-7AEEE21F-7C3A-4BFF-A29C-BA088ED28422

P921

Q33408443-DC43ED57-D94C-4E55-87F4-17180C30542F

P356

1078-0432.CCR-13-0755

P1433

Clinical Cancer Research

P1476

U.s. Food and Drug Administrat ...... treatment of multiple myeloma.

@en

P2093

Albert Deisseroth

http://www.w3.org/2001/XMLSchema#string

Angelica Dorantes

http://www.w3.org/2001/XMLSchema#string

Ann T Farrell

http://www.w3.org/2001/XMLSchema#string

Bahru Habtemariam

http://www.w3.org/2001/XMLSchema#string

Edvardas Kaminskas

http://www.w3.org/2001/XMLSchema#string

Houda Mahayni

http://www.w3.org/2001/XMLSchema#string

Janice Brown

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Bray

http://www.w3.org/2001/XMLSchema#string

Jessica Hawes

http://www.w3.org/2001/XMLSchema#string

Josephine Jee

http://www.w3.org/2001/XMLSchema#string

P304

4559-4563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0755

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23775332

http://www.w3.org/2001/XMLSchema#string

P921